This Article Full Text Full Text (PDF) All Versions of this Article: 92/7/2567    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simon, D. Articles by Czernichow, P. Search for Related Content PubMed PubMed Citation Articles by Simon, D. Articles by Czernichow, P. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology

Early Recombinant Human Growth Hormone Treatment in Glucocorticoid-Treated Children with Juvenile Idiopathic Arthritis: A 3-Year Randomized Study

Department of Pediatric Endocrinology (D.S., P.C.), Robert Debré Teaching Hospital, 75019 Paris, France; Department of Pediatric Rheumatology (A.-M.P., P.Q.), National Reference Center for Rare Diseases, Necker-Enfants Malades Teaching Hospital, 75015 Paris, France; and Department of Radiology (J.C.R.), Cochin Teaching Hospital, 75014 Paris, France

Address all correspondence and requests for reprints to: Dominique Simon, M.D., Hôpital Robert Debré, Service d’Endocrinologie, 48 Boulevard Sérurier, 75019 Paris, France. E-mail: dominique.simon{at}rdb.aphp.fr.

Context: Long-term glucocorticoid therapy adversely affects growth and body composition in children with juvenile idiopathic arthritis (JIA). In previous studies, recombinant human GH (rhGH) halted the progression of these complications without inducing catch-up growth.

Objectives: The objective of the study was to evaluate the impact on growth and body composition of rhGH started early after glucocorticoid initiation and to record adverse effects in children with JIA.

Design: This is a 3-yr randomized controlled study.

Setting: This study was conducted in a teaching hospital.

Patients: Thirty children, 12–15 months into glucocorticoid therapy for severe JIA, were enrolled.

Intervention: Patients received rhGH (0.46 mg/kg·wk) in daily sc injections (n = 15) or no rhGH therapy (n = 15) for 3 yr.

Main Outcome Measure: Difference in height SD score (SDS) change between the two groups was assessed. Height velocity, body composition, and oral glucose tolerance were evaluated yearly.

Results: Mean height SDS increase was larger with rhGH (+0.37 ± 1.5 SDS) than without (–0.96 ± 1.2 SDS) (P = 0.04). Mean height velocity returned to normal within the first year of rhGH treatment and remained normal thereafter. Mean lean mass increase was greater with rhGH treatment (+7.3 ± 2.9 kg vs. +4.4 ± 2.8 kg; P = 0.03). Fat mass and bone mineralization were not significantly different in the two groups. Fasting serum insulin increased significantly in rhGH-treated patients (5.2 ± 16 mIU/liter) compared with untreated controls (–2.3 ± 5 mIU/liter) (P = 0.04); fasting glycemia was unchanged.

Conclusions: rhGH started early in the course of JIA preserved normal growth velocity and height. Although rhGH was well tolerated, carbohydrate metabolism should be monitored closely.

This article has been cited by other articles:

				S. Varma Growth Hormone Treatment for Children on Chronic Corticosteroids AAP Grand Rounds, October 1, 2007; 18(4): 42 - 42. [Full Text] [PDF]